secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2025-02-04T23:59:59+00:00
Accession:  0001493152-25-004793
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack completes 1:20 reverse stock split; first human CBGM study successful with no serious adverse events
--------------------------------------------------------------------------------

- Effective Feb 3, 2025, every 20 pre-split shares combined into 1 share; outstanding shares reduced from ~155.5M to ~7.8M.
- First in-human CBGM study met primary endpoint: no procedure- or device-related serious adverse events from implant through 7 days post-removal.
- Six participants with diabetes mellitus; CBGM sensor lead placed intravascularly in subclavian vein for 4-day in-hospital monitoring.
- Study confirmed CBGM sensor lead function; system accuracy consistent with prior animal studies; next step is long-term clinical trials.
- Ticker GCTK unchanged; new CUSIP 45824Q705; shares trade on split-adjusted basis from Feb 4, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315225004793/0001493152-25-004793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315225004793/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-004793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer